NCPA members to speak in annual FDA listening session on compounding

On June 15, NCPA will be represented at FDA’s annual listening session on compounding by NCPA staff Steve Postal and NCPA members — and meeting presenters — Steve Hoffart and Cheri Garvin. NCPA submitted its written statement for the record ahead of the listening session on compounding, covering concerns with GFI #256 (compounding animal drugs from bulk substances), patient access to compounded bioidentical hormone therapy, drug shortages, and adverse event reporting.